Voyager Therapeutics (NASDAQ:VYGR) Announces Earnings Results, Beats Estimates By $0.08 EPS

Voyager Therapeutics (NASDAQ:VYGR) announced its quarterly earnings data on Thursday. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.08, Zacks reports. The company had revenue of $3.17 million during the quarter, compared to analysts’ expectations of $4.52 million. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR traded up $0.14 during midday trading on Friday, hitting $3.27. The company’s stock had a trading volume of 469,234 shares, compared to its average volume of 651,966. The business’s fifty day simple moving average is $3.42 and its two-hundred day simple moving average is $3.74. Voyager Therapeutics has a 1 year low of $2.93 and a 1 year high of $5.55. The firm has a market capitalization of $197.57 million, a price-to-earnings ratio of -1.66 and a beta of 1.31.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Monday, July 13th. Wall Street Zen cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, HC Wainwright reissued a “buy” rating on shares of Voyager Therapeutics in a report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Voyager Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Hedge Funds Weigh In On Voyager Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its stake in shares of Voyager Therapeutics by 179.3% in the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock valued at $1,674,000 after acquiring an additional 317,927 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Voyager Therapeutics during the 1st quarter worth about $218,000. Acadian Asset Management LLC increased its holdings in Voyager Therapeutics by 863.3% during the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock worth $778,000 after purchasing an additional 206,758 shares during the period. Geode Capital Management LLC raised its position in Voyager Therapeutics by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock valued at $3,474,000 after purchasing an additional 11,929 shares in the last quarter. Finally, American Century Companies Inc. raised its position in Voyager Therapeutics by 5.1% in the 2nd quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock valued at $430,000 after purchasing an additional 6,748 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.